ADIPOQ and type 2 diabetes mellitus: For instance, in post hoc analyses, the effects of Tirzepatide on biomarkers of non-alcoholic fatty liver disease (NAFLD) and fibrosis in patients with T2DM compared to Dulaglutide and placebo for 26 weeks have also been investigated, showing that a higher Tirzepatide dose significantly decreases NAFLD-related biomarkers and increases adiponectin in patients with T2DM [88].